BenevolentAI (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery.
所以我其实对AI+小分子制药的前景偏向于悲观的,业界是对现有AI的Hype居多、学界则是不懂Science和Pharma Industry。当然research还是有很多能做的,比如我最近很关注的一个点是in silicodata generation,即怎么能够去用计算机程序来生成更海量的、能用的数据,以扩大搜索空间。比如这篇工作: 还有一些genomics里面有意思的...
例如,PandaOmics平台(https://pharma.ai/pandaomics/)成功利用多组学数据和生物网络分析,识别出TRAF2和NCK相互作用激酶是抗纤维化治疗的潜在靶点,从而开发出一种特异的TRAF2和NCK相互作用激酶抑制剂(INS018_055)。然而,文献中可能存在的发表偏倚表明,需要采用补充方法来确保识别出新颖且相关的靶点。 “真实世界”数据...
AT THE WORLD'S PHARMA AND BIOTECH COMPANIES, artificial intelligence is increasingly critical to the drug-discovery engine. A 2019 survey by the Pistoia Alliance found that 70% of life sciences researchers use AI, including machine and deep learning, in their work, up from 44% just 2 years ...
公司整合两种商业模式:通过自主研发的Pharma.AI平台提供人工智能驱动的药物发现服务和软件,以及利用自主研发的平台开发自有的临床前在研管线。英矽智能已证明其有能力在18个月内完成识别主要疾病的全新靶点,生成和验证具有该靶点所需特性的新分子...
英矽智能基于人工智能药物研发平台Pharma.AI研发的IPF（特发性肺纤维化）候选药物ISM001-055，于今年7月已启动在中国的1期临床试验，完成了首批健康受试者给药。据悉，这是首个在中国进入临床试验、由人工智能发现和设计的药物。这也意味着，AI制药的能力已经得到初步验证。新药或在明年上半年进入2期临床 在刚刚...
A Roadmap for Pharma Companies The AI revolution in drug discovery will not happen overnight. Even as AI-driven innovations show impressive results, established pharmaceutical companies retain many advantages. These include capital, scientific expertise, development know-how and experience, regulatory expe...
SAE Media Groupis proud to present the 6th AnnualAI in Drug Discovery Conferenceon10th-11th March 2025, inLondon, UK. Join us for the biggest AI in drug discovery event in the UK, that brings together the highest number of big pharma speakers for focused discussions and networking. ...
2. Henstock P. Artificial Intelligence in Pharma: Positive Trends but More Investment Needed to Drive a Transformation. Arch. Pharmacol. Ther. 2020; 2(2): 24–28. Artificial intelligenceBiomoleculesCellular, Molecular and Developmental BiologyDrug discoveryDrug research and developmentPharmacologyProteins...
另据Pharma Intelligence的报告，当前新药研发的整体成功率只有10%，对于小分子药物更是仅有7.5%。大型制药公司研发的投资回报率现在有接近成本的趋势，且预计会进一步下降。因此，新药研发工作越来越需要考虑“成本和成功率的balance”。同时，市场和监管机构对于创新药的要求不断提升，行业内也渴求新技术、新方法的出现...